Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence
Sign Up to like & getrecommendations! Published in 2023 at "Expert Opinion on Drug Discovery"
DOI: 10.1080/17460441.2023.2170348
Abstract: ABSTRACT Introduction Direct-acting SARS-CoV-2 antiviral monoclonal antibodies have been an integral part of therapeutic strategies against COVID-19 pandemic. The monoclonal strategy was jeopardized by the emergence of new variants and resistant strains, making many monoclonal… read more here.
Keywords: tixagevimab; development; cilgavimab; world evidence ... See more keywords
Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis
Sign Up to like & getrecommendations! Published in 2022 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofac283
Abstract: Abstract Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical characteristics of 8 patients who developed COVID-19 soon after receiving tixagevimab-cilgavimab. This study emphasizes the… read more here.
Keywords: severe acute; coronavirus; tixagevimab cilgavimab; cilgavimab ... See more keywords
Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Transplantation"
DOI: 10.1111/ajt.17121
Abstract: The cilgavimab−tixagevimab combination retains a partial in vitro neutralizing activity against the current SARS‐CoV‐2 variants of concern (omicron BA.1, BA.1.1, and BA.2). Here, we examined whether preexposure prophylaxis with cilgavimab−tixagevimab can effectively protect kidney transplant… read more here.
Keywords: tixagevimab; tixagevimab 150; cilgavimab; kidney transplant ... See more keywords
Tixagevimab-Cilgavimab: COVID-19 Pre-Exposure Prophylaxis.
Sign Up to like & getrecommendations! Published in 2022 at "Clinical journal of oncology nursing"
DOI: 10.1188/22.cjon.479-482
Abstract: Tixagevimab-cilgavimab is the only nonvaccine drug currently authorized in the United States for the prevention of COVID-19 infection in individuals who are moderately to severely immunocompromised or unable to receive COVI. read more here.
Keywords: cilgavimab covid; exposure prophylaxis; tixagevimab cilgavimab; cilgavimab ... See more keywords